Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTER-PATH NeoDT
NCT04310397Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2020
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of spartalizumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2020; status: terminated.
02
Drugs
spartalizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04310397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310397.